“基于中国已获批疾病修正治疗,探索复发型多发性硬化的治疗策略”解读  

Interpretation of“Treatment Algorithms of Relapsing Multiple Sclerosis:An Exploration Based on the Available Disease-modifying Therapies in China”

作　　者：谭红梅 全超 TAN Hong-mei;QUAN Chao(Department of Neurology,Huashan Hospitall,,Fudan University,Shanghai,200040,China;National Center for Neurological Disorders,Shanghai 200040,China)

机构地区：[1]复旦大学附属华山医院神经内科,上海200040 [2]国家神经疾病医学中心,上海200040

出　　处：《中国临床神经科学》2024年第5期545-550,共6页Chinese Journal of Clinical Neurosciences

摘　　要：2024年4月13日,神经病学期刊Therapeutic Advances in Neurological Disorders在线发表了题为“基于中国已获批疾病修正治疗,探索复发型多发性硬化的治疗策略”的综述文章,文章基于中国目前已经获批的疾病修正治疗,探讨了适合中国复发型多发性硬化患者的治疗策略。内容涵盖:早期启动治疗、不同疾病活动定义、起始治疗选择、换药评估及药物转换策略。旨在为中国复发型多发性硬化的治疗提供临床参考,尤其是对于治疗经验较少的非专科中心具有一定的临床指导价值。文中将对该综述的治疗策略内容进行介绍和解读。In April 2024,a review paper entitled“Treatment algorithms of relapsing multiple sclerosis:An exploration based on the available disease-modifying therapies in China”has been e-published in Therapeutic Advances in Neurological Disorders,a well-known international neurological journal.The paper explored the treatment algorithms of relapsing multiple sclerosis based on the available disease-modifying therapies in China,including early initiation,the definition of disease activity,options of initiating treatment,evaluation of treatment response and disease-modifying therapies switching algorithms.The paper aimed to establish an optimized treatment algorithm,which will help physicians in China treat multiple sclerosis(MS)patients appropriately,especially physicians who are lack of experience in MS treatment.This interpretation will introduce and highlight the therapeutic strategy content of the review.

关 键 词：复发型多发性硬化 疾病修正治疗 中国治疗策略 治疗评估 

分 类 号：R744.5*1[医药卫生—神经病学与精神病学]